Nevertheless, the compound is relatively well tolerated in mice, and exhibits in vivo activity against mutant KRAS-expressing xenografts, with concomitant mitotic arrest within the tumor, suggesting that its therapeutic index for the treatment of mutant KRAS-expressing cancers may exceed that observed in cellular assays. The gene discussed is KRAS; the disease is neoplasm.